Sean Cassidy
Director of Finance/CFO en Arvinas Operations, Inc. .
Fortuna: 8 M $ al 31/03/2024
Perfil
En la actualidad, Sean A. Cassidy es director financiero de Arvinas, Inc. y director financiero de Arvinas Operations, Inc. (una filial de Arvinas, Inc.) y tesorero de The Friends of Yale New Haven Children's Hospital. En el pasado, el Sr. Cassidy ocupó el cargo de Director Financiero y Vicepresidente de Administración en Renetx Bio, Inc., Director Financiero y Vicepresidente de CuraGen Corp., Director y Contralor en Deloitte & Touche LLP y Director y Contralor en 454 Life Sciences Corp. Obtuvo un MBA y una licenciatura en la Universidad de Connecticut.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ARVINAS, INC.
0.27% | 23/02/2024 | 181 916 ( 0.27% ) | 8 M $ | 31/03/2024 |
Cargos activos de Sean Cassidy
| Empresas | Cargo | Inicio |
|---|---|---|
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Director of Finance/CFO | - |
| The Friends of Yale New Haven Children's Hospital | Treasurer | - |
Antiguos cargos conocidos de Sean Cassidy.
| Empresas | Cargo | Fin |
|---|---|---|
| ARVINAS, INC. | Director of Finance/CFO | 29/02/2024 |
Renetx Bio, Inc.
 Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Director of Finance/CFO | 01/06/2013 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Director of Finance/CFO | 01/10/2009 |
454 Life Sciences Corp.
 454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Director/Board Member | 01/12/2008 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Director/Board Member | 01/05/2001 |
Formación de Sean Cassidy.
| University of Connecticut | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ARVINAS, INC. | Health Technology |
| Empresas privadas | 6 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Renetx Bio, Inc.
Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
454 Life Sciences Corp.
454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Health Services |
| The Friends of Yale New Haven Children's Hospital |
- Bolsa de valores
- Insiders
- Sean Cassidy
